Research progress on melatonin in preventing and treating postmenopausal osteoporosis
10.3760/cma.j.cn112150-20250225-00137
- VernacularTitle:褪黑素防治绝经后骨质疏松的新进展
- Author:
Jiachen WANG
1
;
Zheyun XU
;
Yujie XU
;
Zhifen ZHANG
Author Information
1. 浙江中医药大学第四临床医学院，杭州310053
- Publication Type:Journal Article
- Keywords:
Melatonin;
Postmenopausal osteoporosis;
Bone metabolism;
Osteoblasts;
Osteoclasts;
Antioxidant effects
- From:
Chinese Journal of Preventive Medicine
2025;59(7):1164-1169
- CountryChina
- Language:Chinese
-
Abstract:
Postmenopausal osteoporosis (PMOP), a bone metabolic imbalance disorder induced by estrogen deficiency, necessitates novel prevention and treatment strategies that transcend the constraints of conventional therapeutic approaches. Melatonin, a signaling molecule secreted by the pineal gland, plays a key role in maintaining circadian rhythms and regulating bone metabolism. In recent years, numerous studies both domestically and internationally have demonstrated that melatonin can promote the generation of osteoblasts and osteoclasts, thereby increasing bone density and improving symptoms of osteoporosis. This article reviews the role of melatonin in the prevention of PMOP, aiming to provide new ideas for the diagnosis and treatment of PMOP.
